Cover Image

Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis

Acute GVHD (aGVHD) remains a major cause of mortality in patients undergoing allo-SCT. In particular, the outcome of those patients who fail first-line therapy with glucocorticosteroids is poor. Preliminary reports suggested that the purine analogue pentostatin might be effective for treatment of st...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmitt, Thomas (Author) , Luft, Thomas (Author) , Hegenbart, Ute (Author) , Tran, Thuong Hien (Author) , Ho, Anthony Dick (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: [2011]
In: Bone marrow transplantation
Year: 2011, Volume: 46, Issue: 4, Pages: 580-585
ISSN:1476-5365
DOI:10.1038/bmt.2010.146
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2010.146
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt2010146
Get full text
Author Notes:T. Schmitt, T. Luft, U. Hegenbart, T.H. Tran, A.D. Ho and P. Dreger
Description
Summary:Acute GVHD (aGVHD) remains a major cause of mortality in patients undergoing allo-SCT. In particular, the outcome of those patients who fail first-line therapy with glucocorticosteroids is poor. Preliminary reports suggested that the purine analogue pentostatin might be effective for treatment of steroid-refractory aGVHD. Here, we report on our single-center experience with pentostatin in this condition. From 2005 to 2008, a total of 24 consecutive patients, who had undergone first-line salvage treatment for steroid-refractory aGVHD of the gastrointestinal tract with pentostatin, were identified from 301 patients allografted during that period and retrospectively analyzed. Response to treatment, defined as CR or very good PR (VGPR), was observed in nine patients (38%), with a median time to response of 10 days. Although pentostatin was associated with only moderate myelosuppressive toxicity, if any, 2-year survival was only 17% with five of the nine responders dying from infection (four patients) or recurrent GVHD (one patient). We conclude that pentostatin is a moderately effective therapy for steroid-refractory aGVHD, showing response and outcome rates similar to other clinically used regimens.
Item Description:Published: 21 June 2010
Gesehen am 12.10.2022
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2010.146

Similar Items